Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 179

1.

Biocompatibility studies of fluorescent diamond particles-(NV)~800nm (part V): in vitro kinetics and in vivo localization in rat liver following long-term exposure.

Gerstenhaber JA, Marcinkiewicz C, Barone FC, Sternberg M, D'Andrea MR, Lelkes PI, Feuerstein GZ.

Int J Nanomedicine. 2019 Aug 12;14:6451-6464. doi: 10.2147/IJN.S209663. eCollection 2019.

2.

Long-term biocompatibility of fluorescent diamonds-(NV)-Z~800 nm in rats: survival, morbidity, histopathology, particle distribution and excretion studies (part IV).

Barone FC, Marcinkiewicz C, Li J, Feng Y, Sternberg M, Lelkes PI, Rosenbaum-Halevi D, Gerstenhaber JA, Feuerstein GZ.

Int J Nanomedicine. 2019 Feb 14;14:1163-1175. doi: 10.2147/IJN.S189048. eCollection 2019.

3.

Pilot study on biocompatibility of fluorescent nanodiamond-(NV)-Z~800 particles in rats: safety, pharmacokinetics, and bio-distribution (part III).

Barone FC, Marcinkiewicz C, Li J, Sternberg M, Lelkes PI, Dikin DA, Bergold PJ, Gerstenhaber JA, Feuerstein G.

Int J Nanomedicine. 2018 Sep 17;13:5449-5468. doi: 10.2147/IJN.S171117. eCollection 2018.

4.

Vascular thrombus imaging in vivo via near-infrared fluorescent nanodiamond particles bioengineered with the disintegrin bitistatin (Part II).

Gerstenhaber JA, Barone FC, Marcinkiewicz C, Li J, Shiloh AO, Sternberg M, Lelkes PI, Feuerstein G.

Int J Nanomedicine. 2017 Nov 24;12:8471-8482. doi: 10.2147/IJN.S146946. eCollection 2017.

5.

The prolyl 4-hydroxylase inhibitor GSK360A decreases post-stroke brain injury and sensory, motor, and cognitive behavioral deficits.

Zhou J, Li J, Rosenbaum DM, Zhuang J, Poon C, Qin P, Rivera K, Lepore J, Willette RN, Hu E, Barone FC.

PLoS One. 2017 Sep 7;12(9):e0184049. doi: 10.1371/journal.pone.0184049. eCollection 2017.

6.

First translational 'Think Tank' on cerebrovascular disease, cognitive impairment and dementia.

Barone FC, Gustafson D, Crystal HA, Moreno H, Adamski MG, Arai K, Baird AE, Balucani C, Brickman AM, Cechetto D, Gorelick P, Biessels GJ, Kiliaan A, Launer L, Schneider J, Sorond FA, Whitmer R, Wright C, Zhang ZG.

J Transl Med. 2016 Feb 13;14:50. doi: 10.1186/s12967-016-0806-z.

7.

Endovascular external carotid artery occlusion for brain selective targeting: a cerebrovascular swine model.

Mangla S, Choi JH, Barone FC, Novotney C, Libien J, Lin E, Pile-Spellman J.

BMC Res Notes. 2015 Dec 21;8:808. doi: 10.1186/s13104-015-1714-7.

8.

Computer modeling of ischemic stroke.

Seidenstein AH, Barone FC, Lytton WW.

Scholarpedia J. 2015;10(3). pii: 32015. No abstract available.

9.

Feasibility of near-infrared spectroscopic tomography for intraoperative functional cerebral monitoring: a primate study.

Lee DC, Gevorgyan T, Graber HL, Pfeil DS, Xu Y, Mangla S, Barone FC, Libien J, Charchaflieh J, Kral JG, Ramirez SA, Simpson L, Barbour RL.

J Thorac Cardiovasc Surg. 2014 Dec;148(6):3204-10.e1-2.

10.

Long-term post-stroke changes include myelin loss, specific deficits in sensory and motor behaviors and complex cognitive impairment detected using active place avoidance.

Zhou J, Zhuang J, Li J, Ooi E, Bloom J, Poon C, Lax D, Rosenbaum DM, Barone FC.

PLoS One. 2013;8(3):e57503. doi: 10.1371/journal.pone.0057503. Epub 2013 Mar 7.

11.

Comparison of passive leg raising and hyperemia on macrovascular and microvascular responses.

Bapat M, Musikantow D, Khmara K, Chokshi P, Khanna N, Galligan S, Kamran H, Salciccioli L, Barone FC, Lazar JM.

Microvasc Res. 2013 Mar;86:30-3. doi: 10.1016/j.mvr.2012.12.003. Epub 2012 Dec 19.

PMID:
23261755
12.

Important role for endothelial calveolin-1 in focal cerebral ischemia-induced blood-brain barrier injury.

Gottschall PE, Barone FC.

J Neurochem. 2012 Jan;120(1):4-6. doi: 10.1111/j.1471-4159.2011.07546.x. No abstract available.

13.

A novel calpain inhibitor for treatment of transient retinal ischemia in the rat.

David J, Melamud A, Kesner L, Roth S, Rosenbaum PS, Barone FC, Popp S, Hassen GW, Stracher A, Rosenbaum DM.

Neuroreport. 2011 Sep 14;22(13):633-6. doi: 10.1097/WNR.0b013e32834959c5.

14.

Thrombopoietin protects the brain and improves sensorimotor functions: reduction of stroke-induced MMP-9 upregulation and blood-brain barrier injury.

Zhou J, Li J, Rosenbaum DM, Barone FC.

J Cereb Blood Flow Metab. 2011 Mar;31(3):924-33. doi: 10.1038/jcbfm.2010.171. Epub 2010 Sep 29.

15.

Post-stroke pharmacological intervention: promoting brain recovery from injury in the future.

Barone FC.

Neuropharmacology. 2010 Dec;59(7-8):650-3. doi: 10.1016/j.neuropharm.2010.08.016. Epub 2010 Sep 8. No abstract available.

PMID:
20804774
16.

Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.

Hansen MK, McVey MJ, White RF, Legos JJ, Brusq JM, Grillot DA, Issandou M, Barone FC.

J Cardiovasc Pharmacol Ther. 2010 Jun;15(2):196-202. doi: 10.1177/1074248410362891. Epub 2010 Mar 23.

PMID:
20332533
17.

Pharmacologic interventions for stroke: looking beyond the thrombolysis time window into the penumbra with biomarkers, not a stopwatch.

Chavez JC, Hurko O, Barone FC, Feuerstein GZ.

Stroke. 2009 Oct;40(10):e558-63. doi: 10.1161/STROKEAHA.109.559914. Epub 2009 Sep 10. Review.

PMID:
19745180
18.

Mitogen-activated protein kinase p38alpha and retinal ischemic preconditioning.

Dreixler JC, Barone FC, Shaikh AR, Du E, Roth S.

Exp Eye Res. 2009 Nov;89(5):782-90. doi: 10.1016/j.exer.2009.07.006. Epub 2009 Jul 24.

19.

Vascular cognitive impairment: dementia biology and translational animal models.

Barone FC, Rosenbaum DM, Zhou J, Crystal H.

Curr Opin Investig Drugs. 2009 Jul;10(7):624-37. Review.

PMID:
19579168
20.

Ischemic stroke intervention requires mixed cellular protection of the penumbra.

Barone FC.

Curr Opin Investig Drugs. 2009 Mar;10(3):220-3. Review.

PMID:
19333878
21.

Modulation of LPS-induced pulmonary neutrophil infiltration and cytokine production by the selective PPARbeta/delta ligand GW0742.

Haskova Z, Hoang B, Luo G, Morgan LA, Billin AN, Barone FC, Shearer BG, Barton ME, Kilgore KS.

Inflamm Res. 2008 Jul;57(7):314-21. doi: 10.1007/s00011-007-7157-4.

PMID:
18622687
22.

SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection.

Legos JJ, Lenhard SC, Haimbach RE, Schaeffer TR, Bentley RG, McVey MJ, Chandra S, Irving EA, Andrew A Parsons, Barone FC.

Exp Neurol. 2008 Jul;212(1):53-62. doi: 10.1016/j.expneurol.2008.03.011. Epub 2008 Mar 25.

PMID:
18462720
23.

Inhibition of phosphodiesterase type 4 decreases stress-induced defecation in rats and mice.

Barone FC, Barton ME, White RF, Legos JJ, Kikkawa H, Shimamura M, Kuratani K, Kinoshita M.

Pharmacology. 2008;81(1):11-7. Epub 2007 Aug 28.

PMID:
17726343
24.

Brain MRI and neurological deficit measurements in focal stroke: rapid throughput validated with isradipine.

Lenhard SC, Strittmatter R, Price WJ, Chandra S, White RF, Barone FC.

Pharmacology. 2008;81(1):1-10. Epub 2007 Aug 28.

PMID:
17726342
25.

Carvedilol prevents and reverses hypertrophy-induced cardiac dysfunction.

Barone FC, Willette RN, Nelson AH, Ohlstein EH, Brooks DP, Coatney RW.

Pharmacology. 2007;80(2-3):166-76. Epub 2007 Jun 4.

PMID:
17551266
26.

Cardiovascular disease strategies--directions after the human genome.

Barone FC.

Curr Opin Investig Drugs. 2006 Sep;7(9):789-91. No abstract available.

PMID:
17002255
27.

Endogenous brain protection: models, gene expression, and mechanisms.

Barone FC.

Methods Mol Med. 2005;104:105-84.

PMID:
15454667
28.

Introduction to stroke genomics.

Read SJ, Barone FC.

Methods Mol Med. 2005;104:3-16. Review.

PMID:
15454662
29.

Glucosylceramide synthase activity and ceramide levels are modulated during cerebral ischemia after ischemic preconditioning.

Takahashi K, Ginis I, Nishioka R, Klimanis D, Barone FC, White RF, Chen Y, Hallenbeck JM.

J Cereb Blood Flow Metab. 2004 Jun;24(6):623-7.

PMID:
15181369
30.

Eprosartan improves cardiac performance, reduces cardiac hypertrophy and mortality and downregulates myocardial monocyte chemoattractant protein-1 and inflammation in hypertensive heart disease.

Behr TM, Willette RN, Coatney RW, Berova M, Angermann CE, Anderson K, Sackner-Bernstein JD, Barone FC.

J Hypertens. 2004 Mar;22(3):583-92.

PMID:
15076165
31.
32.

Update on pharmacological strategies for stroke: prevention, acute intervention and regeneration.

Legos JJ, Barone FC.

Curr Opin Investig Drugs. 2003 Jul;4(7):847-58. Review.

PMID:
14619407
33.

Up-regulation of secretory leukocyte protease inhibitor (SLPI) in the brain after ischemic stroke: adenoviral expression of SLPI protects brain from ischemic injury.

Wang X, Li X, Xu L, Zhan Y, Yaish-Ohad S, Erhardt JA, Barone FC, Feuerstein GZ.

Mol Pharmacol. 2003 Oct;64(4):833-40.

PMID:
14500739
34.

The antithrombotic efficacy of lotrafiban (SB 214857) in canine models of acute coronary thrombosis.

Toomey JR, Samanen J, Valocik RE, Koster PF, Barone FC, Willette RN.

Curr Drug Targets Cardiovasc Haematol Disord. 2002 Jun;2(1):13-25.

PMID:
12769654
35.

Strain-dependent response to cerebral ischemic preconditioning: differences between spontaneously hypertensive and stroke prone spontaneously hypertensive rats.

Purcell JE, Lenhard SC, White RF, Schaeffer T, Barone FC, Chandra S.

Neurosci Lett. 2003 Mar 20;339(2):151-5.

PMID:
12614917
36.

Caspase 3 activation is essential for neuroprotection in preconditioning.

McLaughlin B, Hartnett KA, Erhardt JA, Legos JJ, White RF, Barone FC, Aizenman E.

Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):715-20. Epub 2003 Jan 9.

37.

The selective p38 inhibitor SB-239063 protects primary neurons from mild to moderate excitotoxic injury.

Legos JJ, McLaughlin B, Skaper SD, Strijbos PJ, Parsons AA, Aizenman E, Herin GA, Barone FC, Erhardt JA.

Eur J Pharmacol. 2002 Jun 28;447(1):37-42.

PMID:
12106800
38.

Pharmacological interventions for stroke: failures and future.

Legos JJ, Tuma RF, Barone FC.

Expert Opin Investig Drugs. 2002 May;11(5):603-14. Review.

PMID:
11996643
39.

The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension.

Abrahamsen CT, Barone FC, Campbell WG Jr, Nelson AH, Contino LC, Pullen MA, Grygielko ET, Edwards RM, Laping NJ, Brooks DP.

J Pharmacol Exp Ther. 2002 Apr;301(1):21-8.

PMID:
11907153
40.

p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation.

Gao F, Yue TL, Shi DW, Christopher TA, Lopez BL, Ohlstein EH, Barone FC, Ma XL.

Cardiovasc Res. 2002 Feb 1;53(2):414-22.

PMID:
11827692
41.

Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke.

Toomey JR, Valocik RE, Koster PF, Gabriel MA, McVey M, Hart TK, Ohlstein EH, Parsons AA, Barone FC.

Stroke. 2002 Feb;33(2):578-85.

PMID:
11823673
42.

Programmable microchip monitoring of post-stroke pyrexia: effects of aspirin and paracetamol on temperature and infarct size in the rat.

Legos JJ, Mangoni AA, Read SJ, Campbell CA, Irving EA, Roberts J, Barone FC, Parsons AA.

J Neurosci Methods. 2002 Jan 30;113(2):159-66.

PMID:
11772437
43.

Nonpeptide tachykinin receptor antagonists. III. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigs.

Hay DW, Giardina GA, Griswold DE, Underwood DC, Kotzer CJ, Bush B, Potts W, Sandhu P, Lundberg D, Foley JJ, Schmidt DB, Martin LD, Kilian D, Legos JJ, Barone FC, Luttmann MA, Grugni M, Raveglia LF, Sarau HM.

J Pharmacol Exp Ther. 2002 Jan;300(1):314-23.

PMID:
11752131
44.

Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction.

Willette RN, Anderson KM, Nelson AH, Olzinski AR, Woods T, Coatney RW, Aiyar N, Ohlstein EH, Barone FC.

J Cardiovasc Pharmacol. 2001 Oct;38(4):606-17.

PMID:
11588531
45.

Characterisation of gene expression changes following permanent MCAO in the rat using subtractive hybridisation.

Bates S, Read SJ, Harrison DC, Topp S, Morrow R, Gale D, Murdock P, Barone FC, Parsons AA, Gloger IS.

Brain Res Mol Brain Res. 2001 Sep 10;93(1):70-80.

PMID:
11532340
46.

Oxidative inactivation of nitric oxide and endothelial dysfunction in stroke-prone spontaneous hypertensive rats.

Ma XL, Gao F, Nelson AH, Lopez BL, Christopher TA, Yue TL, Barone FC.

J Pharmacol Exp Ther. 2001 Sep;298(3):879-85.

PMID:
11504780
47.

Activation of caspase-3/caspase-3-like activity in rat cardiomyocytes by an RGD peptide, but not the GPIIb/IIIa antagonist lotrafiban.

Erhardt JA, Ohlstein EH, Toomey JR, Gabriel MA, Willette RN, Yue TL, Barone FC, Parsons AA.

Thromb Res. 2001 Jul 15;103(2):143-8. No abstract available.

PMID:
11457472
48.

Stroke genomics: approaches to identify, validate, and understand ischemic stroke gene expression.

Read SJ, Parsons AA, Harrison DC, Philpott K, Kabnick K, O' Brien S, Clark S, Brawner M, Bates S, Gloger I, Legos JJ, Barone FC.

J Cereb Blood Flow Metab. 2001 Jul;21(7):755-78. Review.

PMID:
11435788
49.

Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats.

Barone FC, Coatney RW, Chandra S, Sarkar SK, Nelson AH, Contino LC, Brooks DP, Campbell WG Jr, Ohlstein EH, Willette RN.

Cardiovasc Res. 2001 Jun;50(3):525-37.

PMID:
11376628
50.

p38 activation is required upstream of potassium current enhancement and caspase cleavage in thiol oxidant-induced neuronal apoptosis.

McLaughlin B, Pal S, Tran MP, Parsons AA, Barone FC, Erhardt JA, Aizenman E.

J Neurosci. 2001 May 15;21(10):3303-11.

Supplemental Content

Loading ...
Support Center